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Abstract
Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in
patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis.
Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low
androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
Methods: We searched PubMed, Scopus, Google Scholar, ScienceDirect, and Web of Science databases (1980-2017) to identify
randomized controlled trials or nonrandomized studies investigating the effect of COCs containing progestins with low androgenic
and antiandrogenic activities, including the products containing desogestrel, cyproterone acetate, and drospirenone, on the HPG
axis in patients with PCOS. In this meta-analysis, fixed and random effect models were used. Outcomes of interest were weighted
mean differences (WMD) of hormonal parameters, including the follicle-stimulating hormone (FSH), luteinizing hormone (LH),
LH-to-FSH ratio, estradiol, total testosterone, and sex hormone–binding globulin. Potential sources of heterogeneity were
investigated using meta-regression and subgroup analyses. Subgroup analyses were performed based on the used progestin
compound and treatment duration. We assessed quality of included studies and their risk of bias using Cochrane guidelines.
Publication bias was assessed using Egger test and funnel plot.
Results: COC use was significantly associated with a decrease in gonadotropin levels, including FSH and LH. Use of products
containing cyproterone acetate was associated with a decrease in FSH levels after 3 months (WMD=−0.48; 95% CI −0.81 to
−0.15), 6 months (WMD=−2.33; 95% CI −3.48 to −1.18), and 12 months (WMD=−4.70; 95% CI −4.98 to −4.42) and a decrease
in LH levels after 3 months (WMD=−3.57; 95% CI −5.14 to −1.99), 6 months (WMD=−5.68; 95% CI −9.57 to −1.80), and 12
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months (WMD=−11.60; 95% CI −17.60 to −5.60). Use of COCs containing drospirenone for 6 months decreased FSH
(WMD=−0.93; 95% CI −1.79 to −0.08) and LH (WMD=−4.59; 95% CI −7.53 to −1.66) levels. Data for products containing
desogestrel were few, but this compound generally had no statistically significant influence on gonadotropin levels similar to that
observed with COCs containing cyproterone acetate and drospirenone. Use of COCs was not associated with any significant
change in LH-to-FSH ratio. COCs containing cyproterone acetate showed maximum effect on gonadotropin suppression. COCs
containing cyproterone acetate significantly decreased estradiol concentrations, whereas those containing drospirenone exhibited
no such effect. All COCs demonstrated improvement in androgenic profile and had the same effects on total testosterone and sex
hormone–binding globulin concentrations. Progestin compound and treatment duration had no statistically significant effects on
changing total testosterone and sex hormone–binding globulin levels.
Conclusions: COCs containing cyproterone acetate can effectively suppress gonadotropins, leading to a decrease in androgenic
parameters. Although different products of COCs could significantly suppress the androgenic profile, it seems that products
containing cyproterone acetate are more effective in suppressing gonadotropin and estradiol levels in patients with PCOS.
(JMIR Res Protoc 2018;7(4):e113)  doi: 10.2196/resprot.9024
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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine and
metabolic disorder in reproductive age women [1-3],
characterized by chronic oligo and/anovulation and
hyperandrogenism (HA), which results in infertility, menstrual
irregularities, hirsutism, acne, and alopecia [4]. PCOS is
associated with an increase in risk of metabolic disorders such
as obesity, dyslipidemia, and impaired glucose metabolism,
which in turn increase the risk of diabetes mellitus and
cardiovascular disease [3,5,6]. This endocrine disorder can have
negative effects on the health-related quality of life of these
women [7].
Combined oral contraceptives (COCs) are considered as the
most common symptomatic treatment of PCOS and contain a
combination of estrogen and progestin [8]. COCs are used not
only to regulate menstrual cycle but also to suppress the
hypothalamic-pituitary-gonadal (HPG) axis and improve clinical
and biochemical HA in women with PCOS [9].
The effectiveness of COCs for the treatment of PCOS is well
documented [10]. Previous studies show that COCs affect
androgen synthesis by inhibiting ovarian androgen production
[11-13]. The main potential mechanisms of COC action include
inhibition of folliculogenesis as a result of suppression of
gonadotropin secretion, suppression of ovarian and adrenal
androgen synthesis, inhibition of 5 alpha reductase, and
increased sex hormone–binding globulin (SHBG) [14,15].
Hence, COCs can improve the HPG axis function through a
decrease in gonadotropin and ovarian androgen levels, which
is a major goal of PCOS treatment [16].
Progestin activity of COCs inhibits luteinizing hormone (LH)
secretion and results in a decline in ovarian androgen release
[17]. Current COC products containing newer progestins with
low androgenic or antiandrogenic effects, such as cyproterone
acetate (CA), chlormadinone acetate (CMA), desogestrel (DSG),
and drospirenone (DRSP), are considered to be effective in
decreasing gonadotropin and androgen levels [14,18,19]. In
particular, these progestins are better for women with PCOS
suffering from HA [17].
Although the effect of COCs on the HPG axis of PCOS women
has been introduced before, however, to the best of our
knowledge, there is no other meta-analysis comparing this effect
among COCs with various progesterone components. In our
opinion, this is a valuable piece of knowledge that could provide
some clues for a better understanding of the mechanism of effect
of various COC compounds, which may be helpful in the
decision-making process for treatment options.
This meta-analysis aimed to compare the effects of COCs
containing progestins with low androgenic and antiandrogenic
activities on the HPG axis in patients with PCOS.
Methods
Overview
This systematic review and meta-analysis was designed
according to the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) statement (Multimedia
Appendix 1) [20] and the Cochrane Handbook for Systematic
Reviews of Interventions [21] to answer the following questions:
1. Do COCs affect the HPG axis of women with PCOS?
2. Is there any difference among the effects of COCs on the
HPG axis in women with PCOS?
3. Is there any difference in the effects of these compounds
based on the duration of their use?
The study was approved by the ethics committee of Research
Institute for Endocrine Sciences, Shahid Beheshti University
of Medical Sciences, Tehran, Iran (Registration number:
IR.SBMU.RIES.RES.1394.90).
Search Strategy
PubMed, Scopus, Google Scholar, ScienceDirect, and Web of
Science were searched for clinical trials investigating the
influence of COCs containing progestins with low androgenic
and antiandrogenic activities on the HPG axis in patients with
PCOS from January 1980 to June 2017. After searching for
subheadings of PCOS in MeSH, the following keyword
combinations were selected: [“polycystic ovary syndrome”
AND “contracept*”] and [“polycystic ovary syndrome” AND
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“contraceptives, oral hormonal” OR “pill” OR “progestin”].
Search limitations were human, females, clinical trial, and
English language.
A hand search of the reference lists of all selected papers was
also conducted to prevent missing studies.
Eligibility Criteria
Studies conducted on reproductive age women with PCOS who
were treated with monophasic COCs were selected for this
meta-analysis; these studies were randomized clinical trials
(RCTs) or nonrandomized studies (NRS).
Diagnostic criteria of each study are identified in Multimedia
Appendix 2. In all the included studies, nonclassic congenital
adrenal hyperplasia, hyperprolactynemia, and other HA
etiologies were ruled out. The intervention of interest was COC
containing progestins with low androgenic or antiandrogenic
activities. Follicle-stimulating hormone (FSH), LH, LH-to-FSH
ratio, estradiol (E2), total testosterone (TT), and SHBG levels
were considered as main outcomes of the study.
Exclusion criteria were as follows: (1) women with idiopathic
hirsutism or other types of HA, (2) women with diabetes or
other chronic diseases, (3) use of biphasic or triphasic
contraceptives, (4) use of gonadotropin-releasing hormone
agonist-antagonist and antiandrogen drugs (eg, ketoconazole
and spironolactone), (5) studies with follow-ups of <3 months
or >24 months, (6) use of biphasic and triphasic COCs, (7) use
of progesterone-only compounds, (8) use of metformin in
combination with COC, and (9) treatment groups with
inadequate number of participants for performing meta-analysis
(<1 study).
Only one study had a follow-up of 24 months and was excluded
from the analysis [9]. We also excluded intervention groups
that had no adequate number of study participants for performing
a meta-analysis, including products containing levonorgestrel
(LNG) and gestodene (GSD). In addition, study groups that
assessed metformin + COCs were excluded from the analysis.
Study Selection
We included all relevant RCTs or NRS assessing COC effects
on the HPG axis in reproductive age women with PCOS. At
least one of the following hormonal parameters had to be
reported: FSH, LH, LH-to-FSH ratio, E2, TT, or SHBG. We
considered COCs containing CPA, DRSP, DSG, and CMA as
interventions of interest. Due to inadequate number of studies
that assessed products with LNG and DSG, these were excluded
from the study.
The results of the searches were screened for meeting the
predefined eligibility criteria. All references were entered to the
endnote software. Selection was performed based on their titles,
followed by using a second selection performed by 1 reviewer
(MA), who deleted duplicates and reviewed abstracts of all
remaining records. Any disagreement in the selection of
abstracts was resolved by consensus or by another reviewer
(FRT). Full-text articles for review and data processing were
obtained for all selected abstracts.
Data Extraction
For each study, the following information were extracted:
authors, year of publication, title, study design, characteristics
of study population, type of intervention, outcome
measurements—including FSH, milliunits per milliliters
(mU/mL); LH, mU/mL; E2, picograms per milliliter; TT,
nanograms per milliliter; and SHBG, nanomole per liter—and
analytical methods. After data extraction, all the measurement
units of hormones were identical. Data were extracted from
full-text articles by 2 reviewers (MA and AK) in close
consultation with another reviewer (FRT).
Data of studies were extracted by mean and SD [22]. To prevent
extraction errors, a control check between the final data used
in the meta-analysis and the original publications was performed
by all authors.
Quality Assessment
Two reviewers (MA and AK) assessed the quality of the studies
separately. They were blinded to study author, institution, and
journal name. Disagreement was resolved and adjusted by the
senior reviewer (FRT). A validated quality assessment checklist
for clinical trial as the modified Consolidated Standards of
Reporting Trials (CONSORT) was used to assign a score to
each paper. The quality assessment of RCTs was assessed based
on the 37-item CONSORT checklist. Each of the 37 items
included in CONSORT were scored to compute an overall
quality score (range 0-37). For scoring of the quality of items,
1 point was given if the information for each item was stated
in the study, and 0 was given if the information was not stated
or was unclear. CONSORT was also modified to the NRS,
which were not randomized controlled studies. For modification
of the checklist, questions related to the blinding and
randomization were excluded.
All clinical trial papers were categorized into 4 groups: high,
moderate, low, and very low quality. Studies with scores ≥70%
of the highest level of the CONSORT checklist were considered
as high, 40% to 70% as moderate, 20% to 40% as low, and
<20% as very low quality [23].
Risk of Bias Assessment
Two authors (MA and AK) independently assessed risk of bias.
The risk of bias in each included study was assessed using the
criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions [21,24,25]. Six domains related to
risk of bias were assessed in each included RCTs: (1) random
sequence generation; (2) allocation concealment; (3) blinding
of participants and personnel; (4) blinding of outcome
assessment; (5) incomplete outcome data; and (6) selective
reporting. Review authors’ judgments were categorized as “low
risk,” “high risk,” and “unclear risk” of bias [24].
For NRS, 7 domains were assessed, including (1) confounding,
(2) enrollment of participants in the study, (3) classification of
interventions, (4) deviations from intended, (5) missing data,
(6) measurement of outcomes, and (7) selection of the reported
results. Review authors’ judgments were categorized as “low
risk,” “moderate risk,” “serious risk,” “critical or high risk,”
and “unclear or no information risk” of bias [25].
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We planned to assess outcomes based on the risk of bias in the
following subgroups: (1) low risk, (2) moderate risk, (3)
serious/high/critical risk, and (4) unclear or no information risk.
Statistical Methods
The studies selected assessed the effects of one or more COCs.
Means and SDs of data at baseline and after treatment were
collected. For studies reporting median and range, a conversion
to mean and SD was performed, when possible [26]. Differences
of mean and SD at both baseline and at end of treatment were
calculated, as were standard errors of these differences, using
the Cochrane Reviewers’ Handbook. For effect measures, the
mean difference [27] and related 95% CIs were calculated based
on the means of the pretreatment and those at the end of
treatment levels of FSH, LH, LH-to-FSH ratio, E2, TT, and
SHBG. Therefore, the primary pooled effect analysis was
estimated weighted mean differences (WMD) for the studies
comparing treatment groups of studies. For the end-of-treatment
time point, the assessment (mean/SD) after a 3-, 6-, or 12-month
cycle was used [21].
Heterogeneity tests were assessed by I-squared and chi-squared
tests [28]. Both fixed and random effect models were used in
the study. The random effect estimation method was applied
for significant chi-squared test results (P<.10) or I-squared
greater than 50%.
Subgroup analyses were performed based on COC compound
and duration of use. In addition to funnel plot, Begg test [27]
and Egger test [29] were used to assess publication bias.
Publication bias was found to be significant for P values <.10
to indicate significant asymmetry. For significant results or
asymmetric funnel plot, the trim and fill method (by metatrim)
was used to identify and correct for publication bias. Metatrim
is a command used in the STATA version 12 software
(StataCorp, College Station, TX, USA) for overcoming
publication bias. It simulates studies that have not been
published in literature and assesses whether the results would
be different when there is or there is no publication bias. Indeed,
for significant results or asymmetric funnel plot, the trim and
fill method (by metatrim) was used to identify and correct for
publication bias by adding some study measures [30,31]. We
used meta-regression to evaluate heterogeneity induced by
important variables, including diagnostic criteria of PCO
(Rotterdam; National Institutes of Health, NIH; Androgen
Excess Society, AES]; and others), body mass index (BMI),
and method of assay of different hormones (radioimmunoassay,
chemical/electrochemical luminescence, enzyme, and unknown).
In addition, we used metainf for performing the sensitivity
analysis. We also assessed risk of bias for included studies using
the Risk of Bias tools as per the Cochrane guidelines, which
are tools designed for RCTs and NRS [24,25]. We then
performed a subgroup analysis based on the risk of bias. P
values <.05 were considered significant for all comparisons,
except for heterogeneity, publication bias, and meta-regression,
where .10 was set as the significance level. All analyses were
performed with STATA software, version 12.
Results
Search Results, Study Selection, Study Characteristics,
and Quality Assessment
A total of 1310 studies were retrieved by searching the electronic
databases. After removing duplicates and assessing for quality
appraisal and eligibility criteria, 34 studies were selected for
the final analyses, which had 46 treatment groups (Figure 1 and
Multimedia Appendix 2). Among these, 19 studies were RCTs
and 15 studies were NRS. In all, 6 studies were classified as
high, 20 as moderate, and 8 as low quality; 6 studies were
identified as very low quality and were excluded from the
meta-analysis. In most of the included studies (n=25), PCOS
was diagnosed by Rotterdam criteria. For other studies, NIH
(n=4) and AES criteria (n=2) for diagnosing PCOS were used.
Only 2 studies did not report their PCOS criteria. Also, for one
study, we used the Homburg criteria for diagnosing PCOS.
Ethinyl estradiol (EE) was the estrogenic component of COCs
in all studies, whereas the progestin components were CA, DSG,
DRSP, or CMA. Of 46 study arms, 20 were exposed to EE 35
µg + CA 2 mg [2,4,10,32-47], 17 to EE 30 µg + DRSP 3 mg
[1,4,9,10,19,42,45,48-56], 6 to EE 30 µg + DSG 150 µg and 3
to EE 30 µg + CMA 2 mg (Multimedia Appendix 2) [9,53,57].
The study population consisted of 1224 women with PCOS
with a mean age of 24.20 (95% CI 23.19-25.30) years and a
mean BMI of 24.42 (95% CI 23.83-25.74) kg/m2 (Multimedia
Appendix 2). Sufficient data were collected for treatments of
3, 6, and 12 months but not for treatments of 24 months. All
hormonal measurements of the studies were performed during
the early follicular phase. Only 2 studies did not report days of
hormonal assessment [22,58]. The effects of different COC
treatments are summarized in Table 1 and Multimedia
Appendices 3 and 4.
Follicle-Stimulating Hormone
A total of 13 studies reported effects of COCs on FSH. No study
assessed the effects on FSH of EE + CMA for 3 to 12 months
and EE + DSG for 12 months.
The use of EE + CA for 3 months was significantly associated
with a decrease in FSH concentrations (WMD=−0.48; 95% CI
−0.81 to −0.15), whereas use of EE + DSG or use of EE+ DRSP
were not significantly associated. After 6 months of treatment
with EE + CA (WMD=−2.33; 95% CI −3.48 to −1.18) and
DRSP (WMD=−0.93; 95% CI −1.79 to −0.08), FSH
concentrations decreased, but there was no decrease with EE +
DSG use. Use of EE + CA for 12 months was associated with
a decrease in FSH concentrations (WMD=−4.70; 95% CI −4.98
to −4.42), whereas the use of EE +DRSP was not. A significant
heterogeneity was identified among most comparisons made
with the FSH concentrations (Table 1 and Multimedia
Appendices 3-5).
Luteinizing Hormone
A total of 18 studies reported the effects of COCs on LH. No
study assessed the effects on LH of EE + CMA for 3 to 12
months and EE + DSG for 12 months.
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LH concentrations significantly decreased after 3 months of
treatment with EE + DSG (WMD=−11.68; 95% CI −13.72 to
−9.64) and EE + CA (WMD=−3.57; 95% CI −5.14 to −1.99)
but not with EE + DRSP. After 6 months of treatment with EE
+ CA (WMD=−5.68; 95% CI −9.57 to −1.80) and EE + DRSP
(WMD=−4.59; 95% CI −7.53 to −1.66), LH concentrations
significantly decreased, whereas no significant decrease in
concentration was observed with EE + DSG use (Figure 2). The
use of EE + CA (WMD=−11.60; 95% CI −17.60 to −5.60) for
12 months also decreased LH concentrations, whereas use of
EE + DRSP did not. There was significant heterogeneity among
some comparisons (Table 1 and Multimedia Appendices 3-5).
Figure 1. Flow diagram of literature search and study selection. PCOS: polycystic ovary syndrome; GnRH: gonadotropin-releasing hormone; COC:
combined oral contraceptives.
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Table 1. Effects of different combined oral contraceptives on hormonal parameters in women with polycystic ovary syndrome. ↑ and ↓ indicate increase
and decrease, respectively.
EE + DSGeEE + CMAdEE + DRSPcEEa + CAbHormonal parameters
FSHf
NON/AhNOg↓3 months
NON/A↓↓6 months
N/AN/ANO↓12 months
LHi
↓N/ANO↓3 months
NON/A↓↓6 months
N/AN/ANO↓12 months
LH-to-FSH ratio
NON/ANONO3 months
NON/ANONO6 months
N/AN/ANONO12 months
E2j
N/AN/ANO↓3 months
N/AN/ANO↓6 months
N/AN/ANO↓12 months
TTk
↓↓↓↓3 months
↓↓↓↓6 months
NO↓↓↓12 months
SHBGl
↑↑↑↑3 months
↑NO↑↑6 months
↑↑↑↑12 months
aEE: ethinyl estradiol.
bCA: cyproterone acetate.
cDRSP: drospirenone.
dCMA: chlormadinone acetate.
eDSG: desogestrel.
fFSH: follicle-stimulating hormone.
gNO: no significant effect.
hN/A: not assessed.
iLH: luteinizing hormone.
jE2: estradiol.
kTT: total testosterone.
lSHBG: sex hormone–binding globulin.
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Figure 2. Forest plot of combined oral contraceptives’ effects on luteinizing hormone after 6 months of treatment.
Luteinizing Hormone to Follicle-Stimulating Hormone
Ratio
A total of 13 studies reported the effects of COCs on LH-to-FSH
ratio. No study assessed the effect on LH-to-FSH ratio of EE +
CMA for 3 to 12 months and EE + DSG for 12 months.
The use of EE + DSG, EE + CA, and EE + CMA for 3 to 12
months was not associated with any significant change in
LH-to-FSH ratio (Table 1 and Multimedia Appendices 3-5).
Estradiol
A total of 7 studies reported the effects of COCs on E2, whereas
no study assessed the effect on E2 of EE + CMA and EE + DSG
for 3 to 12 months.
The use of EE + CA for 3 to 12 months significantly decreased
the E2 concentrations; WMDs (95% CI) in these durations of
follow-ups were −5.62 (−10.49 to −0.75), −28.90 (−31.44 to
−26.36), and −32.43 (−46.11 to −18.74), respectively. EE +
DRSP use was not associated with any significant change in E2
concentrations. No significant heterogeneity was identified
among comparisons (Table 1 and Multimedia Appendices 3-5).
Total Testosterone
A total of 30 studies reported the effects of COCs on TT.
The use of various COCs, including EE + DSG (WMD=−0.41;
95% CI −0.73 to −0.08), EE + CA (WMD=−0.25; 95% CI −0.29
to −0.21), and EE + DRSP (WMD=−0.22; 95% CI −0.38 to
−0.05), was associated with a significant decrease in TT after
3 months of treatment; however, there was no decrease after
EE + CMA use. After 6 months of use, all treatments including
EE + DSG (WMD=−0.20; 95% CI −0.36 to −0.04), EE + CA
(WMD=−0.30; 95% CI −0.44 to −0.16), EE + DRSP
(WMD=−0.17; 95% CI −0.23 to −0.11), and EE + CMA
(WMD=−0.24; 95% CI −0.37 to −0.11) decreased TT
concentrations. The 12-month use of EE + CA (WMD=−0.29;
95% CI −0.54 to −0.04), EE + DRSP (WMD=−0.12; 95% CI
−0.22 to −0.03), and EE + CMA (WMD=−0.10; 95% CI −0.17
to −0.03) also decreased TT concentrations, although EE + DSG
use was not associated with any significant change in TT. For
all comparisons made with TT concentrations, significant
heterogeneity was identified (Table 1 and Multimedia
Appendices 3-5).
Sex Hormone–Binding Globulin
A total of 25 studies reported the effects of COCs on SHBG.
Different COCs containing EE + DSG (WMD=99; 95% CI
88.74-109.26), EE + CA (WMD=96.86; 95% CI 47.88-145.84),
EE + DRSP (WMD=100.90; 95% CI 12.50-189.30), and EE +
CMA (WMD=137.73; 95% CI 89.14-186.32) were associated
with increase in SHBG concentrations, following 3 months of
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treatment. After 6 months of treatment, EE + DSG
(WMD=57.35; 95% CI 19.59-95.11), EE + CA (WMD=102.17;
95% CI 82.72-121.63), EE + DRSP (WMD=93.54; 95% CI
63.63-123.45) increased SHBG concentrations, whereas EE +
CMA use was not associated with any significant change in
SHBG. SHBG concentrations were also increased after 12
months of treatment with all COCs, including EE + DSG
(WMD=181.98; 95% CI 20.25-343.71), EE + CA
(WMD=162.10; 95% CI 101.63-222.56), EE + DRSP
(WMD=89.33; 95% CI 41.45-137.21), and EE + CMA
(WMD=9.24; 95% CI 6.65-11.83). There was significant
heterogeneity identified among comparisons (Table 1 and
Multimedia Appendices 3-5).
Publication Bias
The results of Egger test showed a significant publication bias
for FSH (P=.01) and E2 after 6 months (P=.07), and corrections
were performed on the outcomes. Metatrim showed a change
(from mean difference, MD=−1.30; 95% CI −2.14 to −0.46 to
MD=−1.33; 95% CI −2.16 to −0. 49) for FSH after 6 months
but no change for E2 (MD=−8.96; 95% CI −24.16 to 6.24) in
women with PCOS after correcting for publication bias
(Multimedia Appendix 6). Other publication biases were not
significant.
Meta-Regression Analysis
We used meta-regression to evaluate heterogeneity induced by
variables, including diagnostic criteria of PCOS (Rotterdam,
NIH, AES, and other), BMI, and method of assay of different
hormones (radioimmunoassay, chemical/electrochemical
luminescence, enzyme, and unknown). Our univariate
meta-regression analysis showed that BMI has a significant
effect on FSH difference at 6th month compared with baseline
level (beta=.55; P=.096). Diagnostic criteria of PCOS were also
a significant source of heterogeneity for FSH difference at the
6th month from the baseline level (P=.02) and SHBG difference
at the 12th month from the baseline level (beta=−4.21; P=.002).
The method of assay was also a significant source of
heterogeneity for TT difference at the 6th month from the
baseline level (beta=−.29; P=.007) and SHBG difference at the
6th month from the baseline level (beta=44.45; P=.085). None
of the potential confounders had any effect on LH and E2 levels.
As previously mentioned, for meta-regression, a P value <.10
was considered statistically significant.
Our multivariate meta-regression was done only for FSH
difference at the 6th month from the baseline level, which had
more than one source of heterogeneity: BMI and diagnostic
criteria of PCOS. It showed that only diagnostic criteria of PCOS
is a significant source of heterogeneity (beta=−4.46; P=.059).
We did not use multivariate meta-regression for other variables
because none of them had more than 1 source for their
heterogeneity among the 3 variables, including BMI, diagnostic
criteria of PCOS, and method of assay.
Sensitivity Analysis
The results of metainf showed that there are few studies that
can distort the results. Most of the time the point estimates and
95% CIs are in a specified similar limit with others, which
showed homogeneity among the studies. We can hence ignore
the risk of introducing bias by BMI, diagnostic criteria of PCOS,
or method of assay. Details of the sensitivity analysis are
presented in Multimedia Appendix 7.
Risk of Bias Assessment
Multimedia Appendices 8 and 9 show details of risk of bias of
published studies. Most RCT studies were at low risk of bias
of random sequence generation (52%, 10/19), blinding of
participants and personnel (63%, 17/19), and selective outcome
reporting (89%, 17/19; in these studies, some biases were more
probable such as blinding of outcome assessment and incomplete
outcome data (Multimedia Appendix 8). The NRS were not at
a high risk of bias. . They had a low risk bias for classification
of interventions and selection of reported results (Multimedia
Appendix 9).
Generally, most studies had an acceptable validity (low risk of
bias), demonstrating high quality of these studies in most
aspects. Subgroup analysis based on the risk of bias showed no
significant change in outcomes, indicating logical
generalizability of these studies.
Discussion
Principal Findings
This meta-analysis compared the effects of COCs with
progestins containing low androgenic and antiandrogenic
activities on the HPG axis in patients with PCOS. A total of 34
studies involving 1224 women was included in this analysis.
Findings showed that the use of COCs containing CA was
significantly associated with a decrease in gonadotropins (FSH
and LH) and E2 concentrations, whereas COCs containing
DRSP did not change these parameters. Data were insufficient
to assess the effects of COCs containing CMA and DSG on
gonadotropins and E2, but in general these products had no
significant effects on these hormonal parameters. COCs were
not associated with any significant change in the LH-to-FSH
ratio. The use of all COCs was associated with an increase in
SHBG and decrease in TT levels, except for DSG at 12 month
and CMA at 6 month of treatment.
PCOS has a complex pathogenesis and is believed to be a result
of disturbances in gonadotropin secretion. Abnormal secretion
of gonadotropins, particularly LH, from the pituitary gland leads
to abnormal and excessive ovarian theca cell androgens [59].
Estrogen and progestin components of COCs act together to
suppress FSH and LH secretion and the midcycle gonadotropin
surge by a feedback mechanism, which results in a decrease in
ovarian steroidogenesis [49,60,61]. Indeed, suppression of LH
is the major mechanism that mediates the effects of these
products in PCOS patients [62].
This study showed that COC use was significantly associated
with a suppression of gonadotropin (FSH and LH) levels.
Duration of treatment is considered to be an important factor
in the suppression of gonadotropins. In fact, the use of products
containing CA for 3 to 12 months was associated with a decrease
in FSH and LH levels, whereas COCs containing DRSP
decreased these hormones only after 6 months of treatment.
Thus, products containing DRSP generally require a more
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prolonged usage to suppress the gonadotropins. Data for
products containing DSG are limited, but this compound
generally had no influence on gonadotropin levels similar to
that observed with COCs containing CA and DRSP. COCs
containing CA are associated with higher gonadotropin
suppression compared with that of other COCs.
No studies assessed the effect of EE + DSG, EE + CMA, and
EE + GSD on E2 levels. Therefore, data were available only
for evaluating the effect of compounds containing EE 35 µg +
CA 2 mg and EE 30 µg + DRSP 3 mg on E2 levels. This analysis
demonstrated that COCs containing CA significantly decreased
E2 concentrations, whereas COCs containing DRSP exhibited
no such effect. Duration of treatment with COCs was not
significant on E2 concentrations. This review clearly shows that
COCs containing CA are more effective compared with COCs
containing DRSP on E2 levels; however, these data are not
sufficient to assess the effect of other contraceptives on E2.
Testosterone, a major androgen in women, increases in many
PCOS patients. Although all COCs can decrease androgen levels
by gonadotropin suppression, contraceptives with antiandrogen
progestins have additional specific mechanisms in addition to
the main mechanisms to improve HA [16,63]. Therefore, it can
be suggested that gonadotropins are independent of sex steroid
secretion [64]. Similar to all progestins, antiandrogen progestins
inhibit LH and increase clearance of testosterone, which leads
to a decrease in androgen levels [65,66]. These newer progestins
also exert antiandrogenic effects by competing at the receptor
sites with androgens and inhibit 5 alpha-reductase activity
[16,65]. Five alpha reductase enzyme catalyzes testosterone to
dihydrotestosterone [67]. This key enzyme is necessary for
biosynthesis and metabolism of androgens [68]. Adipose tissue
is an important source of active steroid production and
metabolism. It contains the aromatase enzyme that converts
circulating androgens to estrogens. As some estrogens in
premenopausal women originate from the peripheral conversion
of androgens, the plasma concentrations of estrone and E2 may
be significantly correlated with the extent of adipose mass.
Obesity is associated with several abnormalities in androgen
metabolism [69]. Urinary excretion of SHBG is lower in obese
women compared with normal-weight women [70]. Kirschner
et al found that menopausal women with abdominal obesity had
higher testosterone levels than those with peripheral obesity
[71]. Obesity is associated with increased androgen production
rate and metabolic clearance rate; however, the main differences
are higher estrogen and lower SHBG levels, whereas usually
no differences are found in androgen and gonadotropin
concentrations [69].
Interestingly, this study showed that all COCs containing CA,
DRSP, CMA, and DSG can decrease TT concentrations. The
type of COC and duration of treatment with COCs had no
significant effects on TT concentrations. A meta-analysis
assessed the effect of COCs on testosterone concentrations in
healthy women and found that the progestin type of COCs does
not affect the testosterone levels [66]; their findings are
consistent with those of this meta-analysis. However, they did
not evaluate the pituitary hormones and other hormones secreted
by the ovary in women with PCOS.
This review also strongly demonstrates that SHBG significantly
increased during the use of COCs. Progestin compound and
duration of treatment had no important effects on the changes
in SHBG levels.
Comparative studies are not adequate to assess the effect of
COCs on HPG; therefore, this meta-analysis included NRS and
individual arms of RCTs. However, it is well known that
meta-analysis of NRS can produce equally or more precise
findings for a clinical question compared with meta-analysis of
RCTs alone [3,72].
Limitations
This study has several limitations that should be mentioned.
First, there is no single definition for the diagnosis of PCOS
and its components. Second, different studies assessed hormonal
measurements by different methods. Third, some studies did
not assess all hormonal parameters. Finally, some subgroups in
this meta-analysis had limited studies to analyze, which can
affect the robustness of the results. Therefore, additional studies
are required to provide more concrete data to investigate and
confirm the accuracy of this conclusion.
There was significant heterogeneity in most outcomes, which
can reflect clinical heterogeneity related to variability in PCOS
diagnostic criteria; interpretation of laboratory tests; study
population, for example, age; BMI; ethnicity or race; and
methods used to measure hormones. To deal with significant
heterogeneities, we used the random effect model. A majority
of studies included in this analysis used the Rotterdam criteria
for diagnosing PCOS and a limited number used other diagnostic
criteria, such as AES or NIH. Therefore, this meta-analysis has
also included PCOS patients with oligomenorrea and cystic
ovaries without clinical or biochemical HA. The results of this
study showed that diagnostic criteria of PCOS can also be a
source of heterogeneity for FSH concentrations, indicating that
variability in diagnostic criteria can be a cause of differences
in gonadotropin concentrations. However, a sensitivity analysis
showed that most of the time point estimates and 95% CIs are
in a specified limit similar to those of others; hence, we can
ignore the risk of introducing bias by BMI, diagnostic criteria
of PCOS, or method of assay. Some included studies reported
the early follicular phase as the timing of hormonal measurement
without determining its exact time; however, blood samples for
all studies were collected at early follicular phase of the
spontaneous menstrual cycle or progesterone-induced menstrual
bleeding.
To minimize selection bias, study selection was conducted based
on the eligibility criteria, which had been accurately determined
just before the study. A hand search of the reference lists of all
selected papers was also conducted to prevent missing studies.
The pooled estimate of this meta-analysis provides precise
results as it has acceptable risk of bias and publication bias; in
addition, it included studies conducted among reproductive age
women from various regions of the world. Moreover, a subgroup
analysis based on the risk of bias was not associated with any
significant differences in outcomes. Hence, we can rely on the
pooled estimate and the generalizability of these studies.
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In this review, the difference between baseline and posttreatment
levels was calculated to assess the effects of COCs on the HPG
axis. However, subgroup analyses based on different baseline
levels and PCOS phenotypes were not performed because of
the limitations of the existing studies.
Conclusions
This meta-analysis indicates that COC use for 3 to 12 months
can suppress gonadotropins, leading to a decrease in androgenic
profiles in women with PCOS. Although progestin compounds
used and duration of treatment were not effective in reducing
the circulating levels of androgens and SHBG, they were
important in gonadotropin suppression. This study demonstrates
that products containing CA have the greatest suppressive effect
on gonadotropins and E2, indicating that the use of this
compound may be a better alternative for PCOS patients with
impaired gonadotropins. However, because of the limitations
of the data available for comparison of the effects of all COCs
on HPG, the investigators recommend designing further
comparative studies.
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